Department of Health Science and Technology, Aalborg University
Aalborg, Northern Jutland, 9220, Denmark
NCT Number: NCT04509284
Persistent pain after treatment for breast cancer is a major clinical problem, affecting 25-60 % of the patients and is a source of considerable physical disability and psychological distress. Thus, the development of novel interventions to improve pain management for these patients is of clinical importance. Resistance training (RT) is a promising tool to combat a variety of undesirable adverse effects due to breast cancer treatment. Further, research suggests that it may also be able to provide pain-relieving benefits.
Hypothesis: Resistance training will improve pain perception and physical function in the short- and long term compared to a non-training control group.
Looking for future studies?
Notify Me18 year–80 year
Female
Interventional
Not applicable
Aalborg, Northern Jutland, 9220, Denmark
Breast cancer is the most common cancer in women worldwide with more than a million new cases diagnosed every year [1]. Fortunately, due to better treatment options, the population of long-term survivors is increasing. This poses new demands for knowledge on how to manage late effects to the treatment regimen. Persistent pain after treatment for breast cancer is a common and underestimated problem as well as it can be a source of considerable physical disability and psychological distress [2]. Hence, the development of novel interventions to improve pain management is of high clinical relevance. Resistance training (RT) is a promising clinical therapeutic tool to improve a variety of adverse effects to breast cancer treatment [3] and may provide several pain-relieving benefits [4]. However, the efficacy of this modality for managing persistent pain after breast cancer treatment is currently unclear. Therefore, the purpose of this project is to investigate if individualized RT can modulate persistent pain after breast cancer treatment, thereby improving our understanding of how this modality may benefit patients and contribute to clinical guidelines for pain management in this clinical population.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The experimental group will perform a supervised progressive resistance training program, with five exercises for the upper- and lower body (box squat, bench press, trap bar deadlift, bench pull and lat pulldown), 2x/week for a 12 week period. The program will utilize a flexible progression system through three distinct training phases; 1) 2-4 sets of 10-12 repetitions, 2) 2-4 sets of 6-8 repetitions, 3) 2-4 sets of 2-4 repetitions. Number of sets are adjusted within session according to daily readiness while load is adjusted within and between sessions according to number of reps performed. A 3-5min rest period is provided throughout the program.
The control group will be instructed to continue their everyday lifestyle with no specific instruction regarding exercise and/or diet. However, they will be encouraged not to engage in new forms of exercise or physical activity throughout the study period.
Time frame: Baseline and at 3, and 6 months
Between group comparisons of treatment effect (change in pressure pain thresholds) from baseline to follow-up) will be performed. Pressure pain thresholds will be collected with a pressure algometer with a progressive increment in pressure of 30kPa.
Time frame: Baseline and at 3, and 6 months
Pain intensity is collected in two different contexts; 1) recollection for the past 3 months and 2) movement evoked pain during testing and training.
Time frame: Baseline and at 3, and 6 months
1RM box squat, bench press, trapbar deadlift, bench pull and lat pulldown conducted in accordance with the recommendations of the American College of Sports Medicine (ACSM)
Time frame: Baseline and at 3, and 6 months
Active range of motion for the affected shoulder is collected for shoulder flexion, horizontal shoulder flexion/extension, shoulder abduction and internal/external shoulder/rotation
Time frame: Baseline and at 3, and 6 months
Estimates of body fat mass, fat free mass, skeletal muscle mass and bodyfat percentage are collected from bioelectrical impedance using an InBody370 device.
Time frame: Baseline and at 3, and 6 months
Arm circumference is collected to assess potential lymphedema development. A difference in circumference of >10% between arms is considered indicative of lymphedema.
Time frame: Baseline and at 3, and 6 months
IPAQ estimates physical activity level as "low", "moderate" or "high" from the number of days and time per day conducting either hard, moderate or easy physical activity for the pas seven days.
Time frame: Baseline and at 3, and 6 months
The EORCT-C30 QLQ estimates quality of life through a series of questions regarding the extent to which the respondee experience various restrictions in physical function and well-being common in cancer patients, ranging from 1 (not at all) to 4 (A lot) on a four point likert scale.
Time frame: Baseline and at 3, and 6 months
The EORCT-C30 QLQ estimates quality of life through a series of questions regarding the extent to which the respondee experience various restrictions in physical function and well-being common in breast cancer patients, ranging from 1 (not at all) to 4 (A lot) on a four point likert scale.
Time frame: Baseline and at 3, and 6 months
The FACIT-scale estimates fatigue through a series of questions regarding the extent to which the respondee experience various symptoms of fatigue, ranging from 0 (not at all) to 4 (A lot) on a five point likert scale.
Time frame: Baseline and at 3, and 6 months
The MDI estimates mental health through a series of questions regarding the extent to which the respondee experience various symptoms of depression, ranging from 0 (never) to 5 (All the time) on a five point likert scale.
Time frame: At 3 months
The summative process evaluation include the following: 1) Context of the intervention described qualitatively, 2) the dose delivered as %'age of the planed sessions effectively implemented, 3) dose received as %'age of planned sessions effectively received, 4) fidelity measured through the following items: (1) whether the training groups (i.e. same participants every session) during training sessions were consistent; (2) whether the instructors delivered all their sessions as initially scheduled; (3) whether warm-up and training were offered in accordance with the time schedules initially planned; (4) whether the time schedule were respected by participants and instructors and 5) satisfaction, rated as level of agreement with a series of statements on a five-point likert scale 1=strongly disagree, 2=disagree, 3=uncertain, 4=agree, and 5=strongly agree.
Time frame: Every session for 12 weeks.
Daily readiness for exertion is assessed at two levels (mental and physical) prior to the warm up and each exercise on a 0-11 numeric rating scale (0 = no readiness, 10 = maximum readiness. Performance i collected as setsXrepsXload per exercise per session. Perceived level of exertion is assessed through a resistance training specific Rating of Perceived Exertion (RPE) scale based on repetitions in reserve. Movement-evoked pain is assessed per set for each exercise on a 11 point numeric rating scale (0= no pain, 10 = maximum pain).
Aalborg University
Other
Effect of Resistance Training of Persistent Pain After Breast Cancer
Acronym: (ANTRAC)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03912948
Breast Cancer, Breast Diseases
Toulouse, Occitanie, France
View Trial DetailsNCT04842409
Breast Cancer, Breast Diseases
Florence, Italy
View Trial DetailsNCT05452499
Anxiety Disorders, Behavior
Mérida, Yucatán, Mexico
View Trial DetailsNCT03737500
Breast Cancer, Breast Diseases
Pavia, Italy
View Trial Details